Abstract 172P
Background
Pancreatic cancer is a disease with poor prognosis. Stereotactic body radiation therapy (SBRT) is emerging hope to achieve better resectability and local control. Pancreatic cancer treatment results are currently poorly predicted by the best clinical prediction algorithms. Through quantitative imaging analysis, radiomics and dynamic imaging characteristics can offer data on clinical outcomes and build clinical models based on imaging phenotypes or radiomics signatures. The objective of this pilot study was to analyze the association of CT based radiomic features with overall survival (OS) in pancreatic cancer patients treated with SBRT.
Methods
Ten patients of borderline resectable and locally advanced pancreatic cancer were included. All patients received neoadjuvant chemotherapy followed by SBRT and further chemotherapy and then assessed for surgery. Using pyRadiomics, radiomic features of gross tumour volume were extracted using contrast enhanced planning CT images acquired during SBRT planning. All the statistical analysis was performed using R software. Survival rates were analyzed using Kaplan-Meier survival curves.
Results
Three of the 10 patients were resected. Median follow-up was 15 months (range,5-24 months), median OS was 25 months. A total of 851 radiomic features [shape, first order, gray-level co-occurrence matrix (GLCM); grey level size zone matrix (GLSZM), gray-level distance zone matrix (GLDZM), grey level run length matrix (GLRLM) and grey level zone length matrix (GLZLM), gray-level co-occurrence matrix (GLCM); the neighborhood gray-level different matrix (NGLDM)] were extracted. Based on the radiomics score, patients were stratified into low and high risk categories.
Conclusions
This pilot study highlights the potential of CT-based radiomic features in predicting survival in patients with pancreatic cancer treated with chemotherapy followed by SBRT. The identified radiomic features, along with clinical parameters, offer valuable prognostic information that can aid in treatment decision-making and patient counseling. However, a larger number of patients are required to validate the results.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract